SEC Form 4 · accession 0001610717-26-000311
Revolution Medicines, Inc. · RVMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sushil Patel
Director
Period of report
Jun 29, 2026
Accepted (ET)
Jul 1, 2026 · 6:25 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001628171
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 29, 2026 | M | 2,955 | $37.54 | A | 27,236 | D | |
| Common StockF3,F2 | Jun 29, 2026 | S | 300 | $183.1733 | D | 26,936 | D | |
| Common StockF4,F2 | Jun 29, 2026 | S | 900 | $184.5869 | D | 26,036 | D | |
| Common StockF5,F2 | Jun 29, 2026 | S | 1,100 | $185.8991 | D | 24,936 | D | |
| Common StockF6,F2 | Jun 29, 2026 | S | 858 | $186.9157 | D | 24,078 | D | |
| Common StockF7,F2 | Jun 29, 2026 | S | 300 | $187.8267 | D | 23,778 | D | |
| Common StockF2 | Jun 29, 2026 | S | 100 | $188.57 | D | 23,678 | D | |
| Common StockF8,F2 | Jun 29, 2026 | S | 600 | $190.545 | D | 23,078 | D | |
| Common StockF9,F2 | Jun 29, 2026 | S | 541 | $191.8661 | D | 22,537 | D | |
| Common StockF10,F2 | Jun 29, 2026 | S | 881 | $192.6139 | D | 21,656 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F11 | $37.54 | Jun 29, 2026 | M | 2,955 | D | — | Jun 19, 2034 | Common Stock | 2,955 | 13,000 | D |
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by Sushil Patel on March 30, 2026.
- F10The transaction was executed in multiple trades in prices ranging from $192.55 to $192.64, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F11Fully vested.
- F2Includes 1,191 restricted stock units.
- F3The transaction was executed in multiple trades in prices ranging from $182.93 to $183.54, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4The transaction was executed in multiple trades in prices ranging from $184.08 to $184.98, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F5The transaction was executed in multiple trades in prices ranging from $185.37 to $186.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F6The transaction was executed in multiple trades in prices ranging from $186.38 to $187.35, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F7The transaction was executed in multiple trades in prices ranging from $187.46to $188.27, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F8The transaction was executed in multiple trades in prices ranging from $190.44 to $190.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F9The transaction was executed in multiple trades in prices ranging from $191.47 to $192.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.